Treatment Schedulea | Dose (μg/mL) | Ratio of Aberrant Metaphaseb | Cell Countsc | Mean | RICC(%)d | ||
---|---|---|---|---|---|---|---|
6–18 (+S) | 0 | 0 | 4792 | 4689 | 4741 | 100 | |
500 | 0 | 5024 | 4931 | 4978 | 108 | ||
1500 | P | 0 | 4996 | 4774 | 4885 | 105 | |
3000 | P | 2 | 4405 | 4247 | 4326 | 86 | |
3500 | P | 2 | 4158 | 4107 | 4133 | 80 | |
4000 | P | 1 | 3528 | 3491 | 3510 | 59 | |
4500 | TTP | 1 | 3054 | 2971 | 3013 | 42 | |
5000 | TTP | 2 | 2796 | 2756 | 2776 | 34 | |
B[a]P 20 | 30 | 3066 | 3116 | 3091 | 45 | ||
6–18 (-S) | 0 | 0 | 5899 | 5757 | 5828 | 100 | |
500 | 0 | 5525 | 5389 | 5457 | 91 | ||
1500 | P | 1 | 5001 | 4962 | 4982 | 79 | |
1800 | P | 2 | 4243 | 4539 | 4391 | 65 | |
2000 | P | 0 | 3508 | 3445 | 3477 | 42 | |
3000 | P | 2 | 2942 | 2734 | 2838 | 26 | |
4NQO 0.4 | 18 | 3226 | 3148 | 3187 | 35 | ||
24–0 (-S) | 0 | 0 | 5600 | 5444 | 5522 | 100 | |
500 | 1 | 5400 | 5479 | 5440 | 98 | ||
1500 | P | 1 | 4971 | 4971 | 4971 | 85 | |
3000 | P | 1 | 4153 | 4072 | 4113 | 63 | |
4000 | P | 0 | 3863 | 3842 | 3853 | 56 | |
5000 | TTP | 0 | 3652 | 3670 | 3661 | 51 | |
4NQO 0.4 | 21 | 2853 | 2994 | 2924 | 31 | ||
Initial cell count | Cell countsc | Mean | |||||
1754 | 1673 | 1872 | 1750 | 1762 |